Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Dementia01:30

Dementia

687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regioselective pyrrolizidine bis-spirooxindoles as efficient anti-amyloidogenic agents.

European journal of medicinal chemistry·2022
Same author

Microwave-assisted rapid synthesis of spirooxindole-pyrrolizidine analogues and their activity as anti-amyloidogenic agents.

Bioorganic chemistry·2021
Same author

Natural spirocyclic alkaloids and polyphenols as multi target dementia leads.

Bioorganic & medicinal chemistry·2021
Same author

Macrolactam analogues of macrolide natural products.

Organic & biomolecular chemistry·2016
Same author

Polyphenol protection and treatment of hypertension.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2016
Same author

Polyphenols for the prevention and treatment of dementia diseases.

Neural regeneration research·2016

Related Experiment Video

Updated: May 4, 2026

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment
05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

3.8K

Danshen diversity defeating dementia.

Helmut M Hügel1, Neale Jackson1

  • 1School of Applied Sciences & Health Innovations Research Institute, RMIT University, Building 3.1.2 GPO Box 2476, Melbourne, VIC 3001, Australia.

Bioorganic & Medicinal Chemistry Letters
|January 8, 2014
PubMed
Summary

Salvia miltiorrhiza (danshen) shows promise for neuroprotection and treating dementia. Developing danshen nanopharmaceuticals is key to improving its absorption and brain penetration for enhanced therapeutic effects.

Keywords:
Alzheimer’s diseaseChinese herbsDKSKSYYRJJLSIH-OGWKRWJUSA-NDementiaFCXSADRZFLOWMC-AJILYHRGSA-NHPCIHJDWEBXCMS-IYKQUIMVSA-NNeuroprotectionOAWGESYMOMZWAW-ZLECIICXSA-NPGZUORCHJXCZCA-UHFFFAOYSA-NPolyphenolicsTanshinones

More Related Videos

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.7K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K

Related Experiment Videos

Last Updated: May 4, 2026

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment
05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

3.8K
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.7K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K

Area of Science:

  • Pharmacology and Traditional Medicine
  • Neuroscience
  • Drug Delivery Systems

Background:

  • Salvia miltiorrhiza (danshen) is a traditional herb used for cerebral ischemia and cardiovascular diseases.
  • Its compounds exhibit neuroprotective effects, including improving cognitive deficits and combating Alzheimer's disease pathology.
  • However, poor oral bioavailability and limited brain permeability hinder its therapeutic efficacy.

Purpose of the Study:

  • To address the bioavailability and brain penetration challenges of Salvia miltiorrhiza.
  • To explore the potential of developing nanopharmaceutical formulations of danshen constituents.
  • To optimize the absorption, circulation, and blood-brain barrier (BBB) permeability of danshen for enhanced neuroprotection.

Main Methods:

  • In vitro studies assessing neuroprotective properties of Salvia miltiorrhiza constituents.
  • Pharmacokinetic analysis of water and lipid danshen fractions.
  • Investigation into the brain permeability of polyphenolic carboxylate anions at physiological pH.
  • Conceptualization of danshen nanopharmaceuticals and semi-synthetic pro-drug strategies.

Main Results:

  • Salvia miltiorrhiza possesses diverse compounds with potential therapeutic benefits for neurological disorders.
  • Existing danshen fractions demonstrate low oral bioavailability and poor BBB permeability.
  • Polyphenolic carboxylate anions are not readily brain-permeable at physiological pH.

Conclusions:

  • Developing advanced drug delivery systems, such as danshen nanopharmaceuticals, is crucial.
  • Improving biocompatibility, absorption, and BBB permeability is essential for unlocking danshen's full neuroprotective potential.
  • Targeted delivery strategies are needed to overcome pharmacokinetic limitations for treating brain diseases.